BioAmber (BIOA) Misses Q4 EPS by 5c

BioAmber (NYSE: BIOA) reported Q4 EPS of ($0.40), $0.05 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $830 thousand.

For earnings history and earnings-related data on BioAmber (BIOA) click here.

You May Also Be Interested In

• Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
• Goldman Sachs Reinstates BlueScope Steel Limited (BSL:AU) (BLSFY) at Buy
• DA Davidson Downgrades Regions Financial (RF) to Neutral on Potential Revenue Shortfall